Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6604475.pdf
Reference34 articles.
1. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, Janssen EA, Gudlaugsson E, other collaborators of the Multicenter Morphometric Mammary Carcinoma Project (MMMCP) (2007) The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer 43: 527–535
2. Baak JPA, van Dop H, Kurver PHJ, Hermans J (1985) The value of morphometry to classic prognosticators in breast cancer. Cancer 56: 374–382
3. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M, Pintor-Toro JA (2002) Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 32: 306–311
4. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as a prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 96: 1504–1513
5. Desmedt C, Sotiriou C (2006) Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle 5: 2198–2202
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment;Medical Oncology;2023-07-14
2. Analytical Validation of a Novel 6-Gene Signature for Prediction of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative, Early-Stage Breast Cancer;Clinical Chemistry;2022-03-21
3. Cell Cycle Changes, DNA Ploidy, and PTTG1 Gene Expression in HTLV-1 Patients;Frontiers in Microbiology;2020-07-24
4. A prognostic model based on cell-cycle control predicts outcome of breast cancer patients;BMC Cancer;2020-06-16
5. Correlation of securin and Ki67 in invasive breast carcinoma;HISTOL HISTOPATHOL;2019
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3